These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 28629344

  • 1. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
    Tanaka M, Hashimoto Y, Hasegawa C, Deacon S, Eastell R.
    BMC Musculoskelet Disord; 2017 Jun 19; 18(1):267. PubMed ID: 28629344
    [Abstract] [Full Text] [Related]

  • 2. Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.
    Hasegawa C, Kastrissios H, Monteleone J, Ohno T, Umemura T, Ohyama M, Nagase S, Small M, Deacon S, Ogawa M, Ieiri I.
    J Clin Pharmacol; 2014 Aug 19; 54(8):937-48. PubMed ID: 24615681
    [Abstract] [Full Text] [Related]

  • 3. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study.
    Engelke K, Nagase S, Fuerst T, Small M, Kuwayama T, Deacon S, Eastell R, Genant HK.
    J Bone Miner Res; 2014 Mar 19; 29(3):629-38. PubMed ID: 24038152
    [Abstract] [Full Text] [Related]

  • 4. Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
    Eastell R, Dijk DJ, Small M, Greenwood A, Sharpe J, Yamada H, Yuba M, Tanimoto M, Deacon S.
    Osteoporos Int; 2016 Jan 19; 27(1):309-18. PubMed ID: 26446770
    [Abstract] [Full Text] [Related]

  • 5. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
    Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, Kuwayama T, Deacon S.
    J Bone Miner Res; 2014 Feb 19; 29(2):458-66. PubMed ID: 23873670
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study.
    Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T, Deacon S.
    J Bone Miner Res; 2011 Jun 19; 26(6):1303-12. PubMed ID: 21312264
    [Abstract] [Full Text] [Related]

  • 7. An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women.
    Tanaka M, Hashimoto Y, Hasegawa C.
    Bone; 2015 Dec 19; 81():178-185. PubMed ID: 26188109
    [Abstract] [Full Text] [Related]

  • 8. [Cathepsin K antagonists: preclinical and clinical data].
    Gamsjäger M, Resch H.
    Wien Med Wochenschr; 2015 Feb 19; 165(3-4):65-70. PubMed ID: 25572547
    [Abstract] [Full Text] [Related]

  • 9. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women.
    Nagase S, Hashimoto Y, Small M, Ohyama M, Kuwayama T, Deacon S.
    Br J Clin Pharmacol; 2012 Dec 19; 74(6):959-70. PubMed ID: 22533981
    [Abstract] [Full Text] [Related]

  • 10. ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.
    Ochi Y, Yamada H, Mori H, Kawada N, Kayasuga R, Nakanishi Y, Tanaka M, Imagawa A, Ohmoto K, Kawabata K.
    J Bone Miner Metab; 2014 Nov 19; 32(6):645-52. PubMed ID: 24317478
    [Abstract] [Full Text] [Related]

  • 11. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec 19; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
    Nagase S, Ohyama M, Hashimoto Y, Small M, Kuwayama T, Deacon S.
    J Clin Pharmacol; 2012 Mar 19; 52(3):306-18. PubMed ID: 21719717
    [Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
    Hasegawa C, Ohno T, Umemura T, Honda N, Ohyama M, Nagase S, Small M, Deacon S, Ogawa M, Ieiri I.
    J Clin Pharmacol; 2014 Jan 19; 54(1):23-34. PubMed ID: 24115072
    [Abstract] [Full Text] [Related]

  • 14. Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys.
    Yamada H, Ochi Y, Mori H, Nishikawa S, Hashimoto Y, Nakanishi Y, Tanaka M, Bruce M, Deacon S, Kawabata K.
    Bone; 2016 May 19; 86():43-52. PubMed ID: 26921823
    [Abstract] [Full Text] [Related]

  • 15. [New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334].
    Manako J.
    Clin Calcium; 2011 Jan 19; 21(1):64-9. PubMed ID: 21187596
    [Abstract] [Full Text] [Related]

  • 16. Quantitative prediction of bone mineral density by using bone turnover markers in response to antiresorptive agents in postmenopausal osteoporosis: A model-based meta-analysis.
    Wu J, Wang C, Li GF, Tang ET, Zheng Q.
    Br J Clin Pharmacol; 2021 Mar 19; 87(3):1175-1186. PubMed ID: 32692857
    [Abstract] [Full Text] [Related]

  • 17. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.
    Hochberg MC, Silverman SL, Barr CE, Miller PD.
    J Clin Densitom; 2010 Mar 19; 13(2):181-9. PubMed ID: 20347369
    [Abstract] [Full Text] [Related]

  • 18. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA.
    J Bone Miner Res; 2010 May 19; 25(5):937-47. PubMed ID: 19874198
    [Abstract] [Full Text] [Related]

  • 19. Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
    Tanaka M, Hashimoto Y, Sekiya N, Honda N, Deacon S, Yamamoto M.
    J Bone Miner Metab; 2014 Jul 19; 32(4):447-54. PubMed ID: 24114194
    [Abstract] [Full Text] [Related]

  • 20. Cortical bone mineral density is increased by the cathepsin K inhibitor ONO-5334, which leads to a robust increase in bone strength: results from a 16-month study in ovariectomised cynomolgus monkeys.
    Yamada H, Ochi Y, Mori H, Nishikawa S, Hashimoto Y, Tanaka M, Deacon S, Kawabata K.
    J Bone Miner Metab; 2019 Jul 19; 37(4):636-647. PubMed ID: 30357565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.